Professor Awen Gallimore

Co-Director of Systems Immunity Research Institute

: Welsh speaking
: Available for postgraduate supervision

My laboratory is focussed on understanding how the immune system works. We are specifically interested in identifying the correlates of anti-viral and anti-cancer immunity and in using this information to guide the design of new treatments.

I run my lab with Professor Andrew Godkin, clinical academic and College Theme Lead for Immunology.

Detailed information relating to our cancer research can be found by visiting https://www.cancerimmunology.co.uk/

Response to the COVID-19 Pandemic

As an Immunology lab, we have responded to the pandemic by establishing a School-wide COVID-19 literature review to support clinicians and scientists working on COVID-19.

In addition, we are part of a UKRI-funded national consortium of immunologists examining the interplay between SARS-CoV-2 and the immune system. We are also part of a National Core Study to examine anti-viral T cell responses in asymptomatic SARS-CoV-2 infected individuals.

Date
Type

2021

Burnell, S. E. A., Capitani, L., MacLachlan, B. J., Mason, G. H., Gallimore, A. M. and Godkin, A. 2021. Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity. Immunotherapy Advances 2(1), article number: ltab025. (10.1093/immadv/ltab025)
Teijeira Crespo, A. et al. 2021. Pouring petrol on the flames: using oncolytic virotherapies to enhance tumour immunogenicity. Immunology 163(4), pp. 389-398. (10.1111/imm.13323)
Lauder, S. N., Vanhaesebroeck, B. and Gallimore, A. 2021. Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach. British Journal of Cancer 125, pp. 467-469. (10.1038/s41416-021-01285-1)
Thomson, A. et al. 2021. Prognostic significance of interleukin-17A-producing colorectal tumour antigen-specific T cells. British Journal of Cancer 124, pp. 1552-1555. (10.1038/s41416-021-01283-3)
Milutinovic, S., Abe, J., Godkin, A., Stein, J. V. and Gallimore, A. 2021. The dual role of high endothelial venules in cancer progression versus immunity. Trends in Cancer 7(3), pp. 214-225. (10.1016/j.trecan.2020.10.001)
MacLachlan, B. J., Mason, G. H., Greenshields Watson, A., Triebel, F., Gallimore, A., Cole, D. K. and Godkin, A. 2021. Molecular characterization of HLA class II binding to the LAG-3 T cell co-inhibitory receptor. European Journal of Immunology 51(2), pp. 331-341. (10.1002/eji.202048753)
Hanna, S. J. et al. 2021. T cell phenotypes in COVID-19 - a living review. Oxford Open Immunology 2(1) (10.1093/oxfimm/iqaa007)
Codd, A. S. et al. 2021. Neutrophilia, lymphopenia and myeloid dysfunction: A living review of the quantitative changes to innate and adaptive immune cells which define COVID-19 pathology. Oxford Open Immunology 2(1), article number: iqab016. (10.1093/oxfimm/iqab016)
Lauder, S. N., Milutinovic, S., Pires, A., Smart, K., Godkin, A. and Gallimore, A. 2021. Using methylcholanthrene-induced fibrosarcomas to study tumor immunology. In: Methods in Cell Biology., Vol. 163. Elsevier, pp. 59-75., (10.1016/bs.mcb.2020.09.007)

2020

Pires, A. et al. 2020. Immune remodelling of the extracellular matrix drives loss of cancer stem cells and tumor rejection. Cancer Immunology Research 8(12), pp. 1520 - 1531. (10.1158/2326-6066.CIR-20-0070)
Hughes, E. et al. 2020. Primary breast tumours but not lung metastases induce protective anti-tumour immune responses after Treg-depletion. Cancer Immunology, Immunotherapy 69, pp. 2063 - 2073. (10.1007/s00262-020-02603-x)
Lauder, S. N. et al. 2020. Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3. Journal for ImmunoTherapy of Cancer 8(2), article number: e000693. (10.1136/jitc-2020-000693)
Greenshields-Watson, A. et al. 2020. CD4 + T cells recognize conserved influenza A epitopes through shared patterns of V-Gene usage and complementary biochemical features. Cell Reports 32(2), article number: 107885. (10.1016/j.celrep.2020.107885)
Scurr, M. J. et al. 2020. Cancer antigen discovery is enabled by RNA-sequencing of highly purified malignant and non-malignant cells. Clinical Cancer Research (10.1158/1078-0432.CCR-19-3087)

2019

MacLachlan, B. J. et al. 2019. Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope. Journal of Biological Chemistry 294(52), pp. 20246-20258. (10.1074/jbc.RA119.009437)
Appanna, G. D., Pembroke, T. P. I., Miners, K. L., Price, D. A., Gallimore, A. M., Ladell, K. and Godkin, A. J. 2019. Rituximab depletion of intrahepatic B cells to control refractory hepatic autoimmune overlap syndrome. QJM: An International Journal of Medicine 112(10), pp. 793-795. (10.1093/qjmed/hcz161)
Gallimore, A., Quezada, S. A. and Roychoudhuri, R. 2019. Regulatory T cells in cancer: where are we now?. Immunology 157(3), pp. 187-189. (10.1111/imm.13088)
Thomson, A. et al. 2019. The Ussing chamber system for measuring intestinal permeability in health and disease. BMC Gastroenterology 19, article number: 98. (10.1186/s12876-019-1002-4)
Watson, H. A. et al. 2019. L-selectin enhanced T cells improve the efficacy of cancer immunotherapy. Frontiers in Immunology 10, article number: 1321. (10.3389/fimmu.2019.01321)
Besneux, M. et al. 2019. The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design. Cancer Immunology, Immunotherapy 68, pp. 247-256. (10.1007/s00262-018-2266-1)

2018

Jones, E., Gallimore, A. and Ager, A. 2018. Defining high endothelial venules and tertiary lymphoid structures in cancer. In: Tertiary Lymphoid Structures. Methods in Molecular Biology., Vol. 1845. Methods in Molecular Biology Humana Press, pp. 99-118., (10.1007/978-1-4939-8709-2_7)
May, S. et al. 2018. Mbd2 enables tumourigenesis within the intestine while preventing tumour-promoting inflammation. Journal of Pathology 245(3), pp. 270-282. (10.1002/path.5074)
Hill, D. et al. 2018. Hyperactive gp130/STAT3-driven gastric tumourigenesis promotes submucosal tertiary lymphoid structure development. International Journal of Cancer 143(1), pp. 167-178. (10.1002/ijc.31298)
Hughes, E., Scurr, M., Campbell, E., Jones, E., Godkin, A. and Gallimore, A. 2018. T‐cell modulation by cyclophosphamide for tumour therapy. Immunology 154(1), pp. 62-68. (10.1111/imm.12913)
Miles, J. J. et al. 2018. Peptide mimic for influenza vaccination using nonnatural combinatorial chemistry. Journal of Clinical Investigation 128(4), pp. 1569-1580. (10.1172/JCI91512)

2017

Colbeck, E. J., Ager, A., Gallimore, A. and Jones, G. W. 2017. Tertiary lymphoid structures in cancer: drivers of antitumor immunity, immunosuppression, or bystander sentinels in disease?. Frontiers in Immunology 8, article number: 1830. (10.3389/fimmu.2017.01830)
Colbeck, E. J. et al. 2017. Treg depletion licenses T cell-driven HEV neogenesis and promotes tumor destruction. Cancer Immunology Research 5(11), pp. 1005-1015. (10.1158/2326-6066.CIR-17-0131)
Scurr, M. et al. 2017. Effect of modified vaccinia Ankara–5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer: A randomized clinical trial. JAMA Oncology 3(10), article number: e172579. (10.1001/jamaoncol.2017.2579)
Scurr, M. J. et al. 2017. Low-dose cyclophosphamide induces anti-tumor T-cell responses which associate with survival in metastatic colorectal cancer. Clinical Cancer Research, article number: clincanres.0895.2017. (10.1158/1078-0432.CCR-17-0895)
Chen, H. et al. 2017. Synergistic targeting of breast cancer stem-like cells by human γδ T cells and CD8+ T cells. Immunology and Cell Biology 95(7), pp. 620-629. (10.1038/icb.2017.21)
Scurr, M. et al. 2017. MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial.. Journal of Clinical Oncology 35(7), pp. 154-154. (10.1200/JCO.2017.35.7_suppl.154)

2016

Hughes, E., Bloom, A., Paisey, S. J., Smart, K., Ager, A. and Gallimore, A. M. 2016. Treating metastatic disease through manipulation of regulatory T cells. European Journal of Immunology 46, pp. 578-578., article number: 827. (10.1002/eji.201670200)

2015

Colbeck, E. et al. 2015. Eliminating roles for T-bet and IL-2 but revealing superior activation and proliferation as mechanisms underpinning dominance of regulatory T cells in tumors. Oncotarget 6(28), pp. 24649-24659. (10.18632/oncotarget.5584)
Pembroke, T., Gallimore, A. M. and Godkin, A. J. 2015. Tracking the kinetics of intrahepatic immune responses by repeated fine needle aspiration of the liver. Journal of Immunological Methods 424, pp. 131-135. (10.1016/j.jim.2015.04.011)
Ondondo, B. et al. 2015. A distinct chemokine axis does not account for enrichment of Foxp3+ CD4+T cells in carcinogen-induced fibrosarcomas. Immunology 145(1), pp. 94-104. (10.1111/imm.12430)
Scurr, M. J. et al. 2015. Assessing the prognostic value of preoperative carcinoembryonic antigen-specific T-cell responses in colorectal cancer. JNCI: Journal of the National Cancer Institute 107(4), article number: djv001. (10.1093/jnci/djv001)
Costa Bento, D. F. et al. 2015. High endothelial venules are rare in colorectal cancers but accumulate in extra-tumoral areas with disease progression. OncoImmunology 4(3), pp. 653-660., article number: e974374. (10.4161/2162402X.2014.974374)
Ford, C. A. et al. 2015. Oncogenic properties of apoptotic tumor cells in aggressive B cell lymphoma. Current Biology 25(5), pp. 577-588. (10.1016/j.cub.2014.12.059)
Stack, G. et al. 2015. CD200 receptor restriction of myeloid cell responses antagonizes antiviral immunity and facilitates cytomegalovirus persistence within mucosal tissue. PLoS Pathogens 11(2), article number: e1004641. (10.1371/journal.ppat.1004641)

2014

Ondondo, B. et al. 2014. Progression of carcinogen-induced fibrosarcomas is associated with the accumulation of naïve CD4+ T cellsviablood vessels and lymphatics. International Journal of Cancer 134(9), pp. 2156-2167. (10.1002/ijc.28556)
Stacey, M. A. et al. 2014. Neutrophils recruited by IL-22 in peripheral tissues function as TRAIL-dependent antiviral effectors against MCMV. Cell Host and Microbe 15(4), pp. 471-483. (10.1016/j.chom.2014.03.003)

2013

Scurr, M. et al. 2013. Escalating regulation of 5T4-specific IFN- + CD4+ T cells distinguishes colorectal cancer patients from healthy controls and provides a target for in vivo therapy. Cancer Immunology Research 1(6), article number: 416. (10.1158/2326-6066.CIR-13-0035)
Lauder, S. N. et al. 2013. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. European Journal of Immunology 43(10), pp. 2613-2625. (10.1002/eji.201243018)
Scurr, M. J. et al. 2013. Highly prevalent colorectal cancer-infiltrating LAP+ Foxp3- T cells exhibit more potent immunosuppressive activity than Foxp3+ regulatory T cells. Mucosal Immunology n/a (10.1038/mi.2013.62)
Ondondo, B., Jones, E., Godkin, A. J. and Gallimore, A. M. 2013. Home sweet home: The tumor microenvironment as a haven for regulatory T cells. Frontiers in Immunology 4, article number: 197. (10.3389/fimmu.2013.00197)
Pembroke, T., Gallimore, A. and Godkin, A. 2013. Flow cytometry makes all the difference. Journal of Hepatology 59(4), pp. 909-910. (10.1016/j.jhep.2013.05.047)
Pembroke, T., Christian, A., Jones, E., Hills, R. K., Wang, E. C. Y., Gallimore, A. M. and Godkin, A. J. 2013. The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon treatment. Gut n/a (10.1136/gutjnl-2013-304472)
Pembroke, T., Gallimore, A. and Godkin, A. 2013. Rapid innate control of antigen abrogates adaptive immunity. Immunology 138(4), pp. 293-297. (10.1111/imm.12048)
Gallimore, A. M. and Godkin, A. J. 2013. Epithelial barriers, microbiota, and colorectal cancer. New England Journal of Medicine 368(3), pp. 282-284. (10.1056/NEJMcibr1212341)

2012

Humphreys, I. R. et al. 2012. Avidity of influenza-specific memory CD8+T-cell populations decays over time compromising antiviral immunity. European Journal of Immunology 42(12), pp. 3235-3242. (10.1002/eji.201242575)
Hindley, J. P. et al. 2012. T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T cell depletion. Cancer Research 72(21), pp. 5473-5482. (10.1158/0008-5472.CAN-12-1912)
Scurr, M. J., Gallimore, A. M. and Godkin, A. J. 2012. T cell subsets and colorectal cancer: discerning the good from the bad. Cellular Immunology 279(1), pp. 21-24. (10.1016/j.cellimm.2012.08.004)
Pembroke, T. et al. 2012. Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4+T-cell immunity. European Journal of Immunology 42(9), pp. 2383-2394. (10.1002/eji.201142072)
Twohig, J. P. et al. 2012. The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4+ and CD8+ T-cell immunity. The FASEB Journal 26(8), pp. 3575-3586. (10.1096/fj.11-200618)
Kempshall, E., Thebault, S., Morgan, B. P., Harris, C. L. and Gallimore, A. M. 2012. Complement-induced protection: an explanation for the limitations of cell-based tumour immunotherapies. Immunology and Cell Biology 90(9), pp. 869-871. (10.1038/icb.2012.30)
Pembroke, T., Wang, E. C. Y., Gallimore, A. M. and Godkin, A. J. 2012. PMO-174 Intrahepatic natural killer cell phenotyping and functional analysis by fine needle aspiration in chronic HCV infection. Gut 61(S2), pp. A144-A145. (10.1136/gutjnl-2012-302514b.174)
Scurr, M. J., Gallimore, A. M. and Godkin, A. J. 2012. PMO-088 A large proportion of colorectal tumour-infiltrating CD4+ T cells are suppressive irrespective of FOXP3 expression. Gut 61(S2), article number: A109. (10.1136/gutjnl-2012-302514b.88)
Cole, D. et al. 2012. Modification of the carboxy-terminal flanking region of a universal influenza epitope alters CD4+ T-cell repertoire selection. Nature Communications 3, article number: 665. (10.1038/ncomms1665)
Betts, G. J. et al. 2012. Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut 61(8), pp. 1163-1171. (10.1136/gutjnl-2011-300970)

2011

Clement, M. et al. 2011. Anti-CD8 antibodies can trigger CD8+ T cell effector function in the absence of TCR engagement and improve peptide-MHCI tetramer staining. The Journal of Immunology 187(2), pp. 654-663. (10.4049/jimmunol.1003941)
Lauder, S. N. et al. 2011. Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity. Thorax 66(5), pp. 368-374. (10.1136/thx.2010.150318)
Hindley, J. P. et al. 2011. Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. Cancer Research 71(3), pp. 736-746. (10.1158/0008-5472.CAN-10-1797)
Ruge, F. et al. 2011. Delineating immune-mediated mechanisms underlying hair follicle destruction in the mouse mutant defolliculated. Journal of Investigative Dermatology 131(3), pp. 572-579. (10.1038/jid.2010.379)
Godkin, A. J. and Gallimore, A. M. 2011. Setting the threshold for extra-thymic differentiation of Foxp3+ Tregs: TGF-β-dependent and T-cell autonomous. European Journal of Immunology 41(5), pp. 1218-1220. (10.1002/eji.201141576)

2010

Lauder, S. N., Smart, K., Ondondo, B., Fielding, C. A., Godkin, A. J., Jones, S. A. and Gallimore, A. M. 2010. A critical role for interleukin-6 in limiting influenza-induced pathology and generating heterosubtypic immunity [Abstract]. Immunology 131(S1), pp. 186. (10.1111/j.1365-2567.2010.03390.x)
Cuff, S., Dolton, G. M., Matthews, R. J. and Gallimore, A. M. 2010. Antigen specificity determines the pro- or antitumoral nature of CD8+ T cells. The Journal of Immunology 184(2), pp. 607-614. (10.4049/jimmunol.0804089)
Richards, H. C., Williams, A. S., Jones, E., Hindley, J. P., Godkin, A. J., Simon, A. K. and Gallimore, A. M. 2010. Novel role of regulatory T cells in limiting early neutrophil responses in skin. Immunology 131(4), pp. 583-592. (10.1111/j.1365-2567.2010.03333.x)

2009

Gallagher, K. M. E., Lauder, S. N., Rees, I. W., Gallimore, A. M. and Godkin, A. J. 2009. Type I interferon (IFNα) acts directly on human memory CD4+ T cells altering their response to antigen. The Journal of Immunology 183(5), pp. 2915-2920. (10.4049/jimmunol.0801607)
Baalasubramanian, S., Longhi, M. P., Gallagher, K. M. E., Betts, G. J., Morgan, B. P., Godkin, A. J. and Gallimore, A. M. 2009. CD59 blockade enhances antigen-specific CD4+ T cell responses in humans: a new target for cancer immunotherapy?. The Journal of Immunology 182(9), pp. 5203-5207. (10.4049/jimmunol.0804243)

2008

Jones, G. W. et al. 2008. TL1A/TNFSF15 promotes a STAT1-mediated suppression of IL-17-secreting T-helper cells [Abstract]. Immunology 125(s1), pp. 62-62. (10.1111/j.1365-2567.2008.02974.x)
Morton, J. et al. 2008. Circulating neutrophils maintain physiological blood pressure by suppressing bacteria and IFN -dependent iNOS expression in the vasculature of healthy mice. Blood 111(10), pp. 5187-5194. (10.1182/blood-2007-10-117283)
Longhi, M. P. et al. 2008. Interleukin-6 is crucial for recall of influenza-specific memory cd4+ t cells. PLoS Pathogens 4(2), article number: e1000006. (10.1371/journal.ppat.1000006)
Richards, H. C., Longhi, M. P., Wright, K. L., Gallimore, A. M. and Ager, A. 2008. CD62L (L-Selectin) down-regulation does not affect memory T cell distribution but failure to shed compromises anti-viral immunity. Journal of Immunology 180(1), pp. 198-206.
Gallimore, A. M. and Simon, A. K. 2008. Positive and negative influences of regulatory T cells on tumour immunity. Oncogene 27(45), pp. 5886-5893. (10.1038/onc.2008.269)

2007

Boulter, J. M., Schmitz, N., Sewell, A. K., Godkin, A. J., Bachmann, M. F. and Gallimore, A. M. 2007. Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. European Journal of Immunology 37(3), pp. 798-806. (10.1002/eji.200636743)
Simon, A. K. et al. 2007. Regulatory T cells inhibit Fas ligand induced innate and adaptive tumour immunity. European Journal of Immunology 37(3), pp. 758-767. (10.1002/eji.200636593)
Gallimore, A. M. and Godkin, A. J. 2007. Regulatory T cells and tumour immunity - observations in mice and men. Immunology 123(2), pp. 157-163. (10.1111/j.1365-2567.2007.02748.x)
Betts, G., Twohig, J. . P., Van den Broek, M., Sierro, S., Godkin, A. J. and Gallimore, A. M. 2007. The impact of regulatory T cells on carcinogen-induced sarcogenesis. British Journal of Cancer 96(12), pp. 1849-1854. (10.1038/sj.bjc.6603824)
Betts, G. J., Godkin, A. J. and Gallimore, A. M. 2007. Reply: forkhead box P3-positive regulatory T cells in immune surveillance and cancer. British Journal of Cancer 97, pp. 1017-1018. (10.1038/sj.bjc.6603940)

2006

Wise, M. P., Gallimore, A. M. and Godkin, A. J. 2006. T-Cell costimulation [Letter]. New England Journal of Medicine 355(24), pp. 2594-2595. (10.1056/NEJMc062767)
Betts, G. J., Clarke, S. L., Richards, H. E., Godkin, A. J. and Gallimore, A. M. 2006. Regulating the immune response to tumours. Advanced Drug Delivery Reviews 58(8), pp. 948-961. (10.1016/j.addr.2006.05.006)

2005

Longhi, M. P., Baalasubramanian, S., Omidvar, N., Morgan, B. P. and Gallimore, A. M. 2005. Cutting edge: murine CD59a modulates antiviral CD4+ T cell activity in a complement-independent manner. Journal of Immunology 175(11), pp. 7098-7102.
Richards, H. E., Simon, A. K., Jones, E., Williams, A. S., Screaton, G. R. and Gallimore, A. M. 2005. Inhibition of innate immune responses to tumours by CD4+CD25+ regulatory T cells [Abstract]. Immunology 116(s1), pp. 36-36. (10.1111/j.1365-2567.2005.02287.x)
Clarke, S. L., Betts, G. J., Wright, K. L., El-Shanawany, T., Plant, A., Gallimore, A. M. and Godkin, A. J. 2005. Analysis of CD4(+)CD25(hi) cells in peripheral blood and lymph nodes of patients with colorectal cancer. Immunology 116(1), pp. 37-37. (10.1111/j.1365-2567.2005.02287.x)

2003

Jones, E., Price, D., Dahm-Vicker, M., Cerundolo, V., Klenerman, P. and Gallimore, A. 2003. The influence of macrophage inflammatory protein-1alpha on protective immunity mediated by antiviral cytotoxic T cells. Immunology 109(1), pp. 68-75. (10.1046/j.1365-2567.2003.01636.x)

2002

Simon, A. K., Gallimore, A. M., Jones, E., Sawitzki, B., Cerundolo, V. and Screaton, G. R. 2002. Fas ligand breaks tolerance to self-antigens and induces tumor immunity mediated by antibodies. Cancer Cell 2(4), pp. 315-322. (10.1016/S1535-6108(02)00151-4)
Golgher, D., Jones, E., Powrie, F., Elliot, T. and Gallimore, A. M. 2002. CD25+ regulatory cells uncover immune responses to shared tumour rejection antigens. European Journal of Immunology 32(11), pp. 3267-3275. (10.1002/1521-4141(200211)32:11<3267::AID-IMMU3267>3.0.CO;2-1)

1999

Bachmann, M. F., Gallimore, A. M., Linkert, S., Cerundolo, V., Lanzavecchia, A., Kopf, M. and Viola, A. 1999. Developmental regulation of Lck targeting to the CD8 coreceptor controls signaling in naive and memory T cells. Journal of Experimental Medicine 189(10), pp. 1521-1530.

1998

Gallimore, A. M., Hombach, J., Dumrese, T., Rammensee, H., Zinkernagel, R. M. and Hengartner, H. 1998. A protective cytotoxic T cell response to a subdominant epitope is influenced by the stability of the MHC class I/peptide complex and the overall spectrum of viral peptides generated within infected cells. European Journal of Immunology 28(10), pp. 3301-3311.
Gallimore, A. M., Hengartner, H. and Zinkernagel, R. 1998. Hierarchies of antigen-specific cytotoxic T-cell responses. Immunological Reviews 164, pp. 29-36. (10.1111/j.1600-065X.1998.tb01205.x)
Gallimore, A. M., Schwarz, K., van den Broek, M., Hengartner, H. and Groettrup, M. 1998. The proteasome inhibitor lactacystin prevents the generation of an endoplasmic reticulum leader-derived T cell epitope. Molecular Immunology 35(10), pp. 581-591.
Gallimore, A. M., Dumrese, T., Hengartner, H., Zinkernagel, R. M. and Rammensee, H. G. 1998. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. Journal of Experimental Medicine 187(10), pp. 1647-1657.

1996

Gotch, F., Gallimore, A. M. and McMichael, A. 1996. Cytotoxic T cells--protection from disease progression--protection from infection. Immunology Letters 51(1-2), pp. 125-128. (10.1016/0165-2478(96)02566-7)

1995

Gallimore, A. M. et al. 1995. Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Natural Medicines 1(11), pp. 1167-1173.
Boyson, J. E. et al. 1995. The MHC E locus in macaques is polymorphic and is conserved between macaques and humans. Immunogenetics 41(2-3), pp. 59-68. (10.1007/BF00182314)
Rowland-Jones, S. et al. 1995. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Natural Medicines 1(1), pp. 59-64.

1993

Gotch, F. et al. 1993. Cytotoxic T cells in HIV2 seropositive Gambians. Identification of a virus-specific MHC-restricted peptide epitope. The Journal of Immunology 151(6), pp. 3361-3369.

Although the main job or our immune system is to protect us from infection by pathogens, it has recently it has become apparent that it is possible to persuade the immune system to recognise and kill cancer. In fact, new medicines have been made which boost the immune systems' ability to recognise cancer. This type of treatment is called immunotherapy.

The problem is that so far, immunotherapy only works for some patients with certain types of cancer. Every cancer is different and the conditions that allow a good immune response to develop in a skin cancer are different to those needed to allow a good immune response to develop in a breast cancer. We know that cancers can put up barriers which help them resist immune attack – variations on these barriers exist in different cancers meaning that immunotherapies must be tailored to overcome the obstacles that a particular cancer type brings.

My laboratory is focussed on identifying and overcoming barriers to successful immunotherapy. Specifically, we are trying to understand how a population of immune cells, called regulatory T cells act to suppress anti-cancer immune responses and how they can be disabled to promote tumour immunity. In addition, we are examining tumour blood vessels and asking how we can manipulate these in order to allow immune cells better access to tumours in order that they can more efficiently find and kill their targets.

I deliver lectures and tutorials in Immunology to undergraduates in Medicine and Pharmacy.

SSC Tutorials and Lab Based Projects – Medical Students

European Society of Immunology Summer School in Sardinia 2009, 2011 and 2013, 2017.

John Humphreys Summer School, Havana, Cuba, 2012

External Examiner for BSc (HONS) in Immunology at Glasgow University 1.10.14 – 30.9.18

I am a Professor at the Division of Infection and Immunity, Cardiff University. I gained a DPhil in 1995 in Professor Andrew McMichael's laboratory in Oxford, studying T cell responses to simian and human immunodeficiency viruses (SIV and HIV). With a Wellcome Trust travelling fellowship I subsequently moved to the laboratory of the Nobel laureate Professor Rolf Zinkernagel in Zurich to further study factors governing anti-viral immunity.

I then established my own laboratory with further Wellcome Trust funding at the Nuffield Department of Medicine in Oxford. At this time, the I started to investigate how lessons learnt from studying anti-viral immunity could be applied to cancer immunology. Specifically, my group focussed on regulatory T cells and were amongst the first to demonstrate that this T cell sub-population inhibited effective anti-cancer T cell responses. I moved to Cardiff in 2002, shortly afterwards gainin a senior fellowship from the MRC to expand the lab. The Cardiff lab, which currently receives its funding from Cancer Research UK, Cancer Research Wales, The Wellcome Trust and Breast Cancer Now takes basic research using animal models of cancer through to testing novel immunotherapies in patients.

Currently, I am the College of Life Sciences Cancer Theme Lead.

Honours and awards

Awards

1995 – 1998

Wellcome Trust Travelling Fellowship

University of Zurich, Switzerland.

1998 – 1999

Wellcome Trust Travelling Fellowship

University of Oxford.

2000 – 2005

Wellcome Trust Career Development Fellowship

University of Oxford / Cardiff University

2006 – 2011

MRC Non-Clinical Senior Fellowship

Cardiff University

2011 – 2016

Wellcome Trust University Award

Cardiff University

Professional memberships

Treasurer of BSI Cancer Immunology Affinity Group.

Member of the British Society for Immunology (BSI) – National Cancer Research Institute, Cancer Immunology Steering Group

Academic positions

2013 - present: Professor, Cardiff University

2008 - 2013: Reader, Cardiff University

2002 - 2008: Lecturer / Senior Lecturer, Cardiff University

1999 - 2002: Career Development Fellow, Oxford University

1998 - 1999: Postdoctoral researcher, Oxford University

1995 - 1998: Postdoctoral researcher, University of Zurich

1991 - 1995: DPhil student, Oxford University

Committees and reviewing

Editorial Duties:

Review Editor Frontiers in Immunology since 2011

Associate Editor of Immunology since June, 2012

Member of Editorial Board Cancer Research 2013 – 2016

Grant Review / Board Memberships:

2016 - Member – Vice-chair - Chair of Cancer Research UK "Immunology Expert review Panel"

2017 – 2021 Member of Cancer Research UK Discovery Research Committee

2017 - 2023 Worldwide Cancer Research panel grant

2018 - Reviewer for the Cancer Research Center (CRC) Zürich (annual).

2018 - Reviewer for the Association of Italian Cancer Research (annual).

2019 – Invited Member of British Society for Immunology (BSI) – National Cancer Research Institute, Cancer Immunology Steering Group

2019 - 2022 Invited member of Canada Immunotherapy Network Research Management Committee (BioCanRx)

2020 Cancer Research UK Member Panel Quinquennial Review of Cancer Research UK Drug Discovery Units

Recently Completed

Ana Pires Exploring the Reciprocal Relationship Between the Immune System and the Tumour Microenvironment

Stefan Milutinovic Exploring the Reciprocal Relationship Between the Immune System and the Tumour Microenvironment

Currently Supervising

Jake Scott Targeting the Vasculature to Improve cancer

Carissa Wong Addressing cellular interactions in tumours in vivo to control tumour immunity

Jessica Oliver Harnessing the Immune Response to Radiotherapy

Co-supervising

Valentina Bart An Objective Systems Approach to Dissect the Contribution of Macrophages to Cancer Growth and Metastasis

Lorenzo Capitani Targeting LAG3+ T Cells for Cancer Immunotherapy

Alicia Crespo Establishing a Potent and Highly Tumour Selective Immuno-Oncolytic Virotherapy for Colorectal Cancer

Rebecca Wallace Development of Precision Virotherapies Capable of evading Anti-vector Immunity

Eleanor Bird Investigating Links between Regulatory T Cell Depletion and Psychosis

Current Activities

*Cancer Research Webinars and YouTube videos produced to discuss and share cancer research developments during the COVID-19 pandemic.

*Ongoing Wellcome Trust ISSF-funded project to develop a computer game to promote an understanding of the interactions between cancer and the immune system.

Past Activities

*Television documentary entitled “Cancer Wars” shown on BBC World

* Regular participation in Science and Health day School of Medicine, Cardiff.

* Contribution to cancer charity newsletters (Tenovus, WCRF)

* BBC Wales Radio Interview and S4C news interviews.

* Won Wellcome Trust Institutional Strategic Support Funds (ISSF) for a project designed to allow schoolchildren to use their artistic vision to express their understanding of biomedical science, 2015/16. http://www.walesonline.co.uk/news/local-news/merthyr-tydfil-pupils-created-artwork-11000816 Facebook:

https://www.facebook.com/media/set/?set=a.246548445680853.1073741833.100819893587043&type=3

* Won a “Systems Immunity University Research Institute” award for a project designed to introduce the concept of big data to primary school children and to explore links between philosophy and immunology. http://www.cardiff.ac.uk/news/view/384555-bridging-immunology-and-philosophy

*Participation at the Eisteddfod including science stalls and speaking events.

* Regular hosting of events to discuss cancer research with patients, their families and friends (often in partnership with cancer charities.

* Speaker at Cardiff CRUK sponsored “Young Art” competition, Cardiff. March 2019.

* Rogue Cells Exhibition Stand, Techniquest. March, 2019.

Contact Details

GallimoreAM@cardiff.ac.uk
+44 29206 87012
Henry Wellcome Building for Biomedical Research, Room Third Floor, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN

Cardiff University Cancer Symposium 2023: a showcase of innovative new research by our early career researchers